Notch1 Gene Silenced by RNAi Inhibits Oncogenicity of Myeloma Cell Line.

Mei-Ling LI; Mei-Qiong CHEN; Peng ZHANG; Quan-Yi LU

Return

Notch1 Gene Silenced by RNAi Inhibits Oncogenicity of Myeloma Cell Line.

VernacularTitle:RNAi沉默Notch1基因对多发性骨髓瘤细胞致瘤性的影响
Author: Mei-Ling LI ¹ ; Mei-Qiong CHEN ² ; Peng ZHANG ² ; Quan-Yi LU ³
Author Information

1. Department of Hematology, The Affiliated Zhongshan Hospital of Xiamen University, Xiamen 361004, Fujian Province, China; Department of Hematology, The Third Hospital of Guizhou Medical University, Duyun 558000, Guizhou Province, China.
2. Department of Hematology, The Affiliated Zhongshan Hospital of Xiamen University, Xiamen 361004, Fujian Province, China.
3. Department of Hematology, The Affiliated Zhongshan Hospital of Xiamen University, Xiamen 361004, Fujian Province, China. E-mail:quanyilu@hotmail com.
Publication Type:Journal Article
From: Journal of Experimental Hematology 2017;25(6):1685-1689
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo investigate the effect of Notch1 gene silencing by RNA interference on oncogenicity of multiple myeloma cells in NOD/SCID mice.
METHODSTargeting-silenced Notch1 gene was target-sotenced by transfection of Notch1-shRNA in multiple myeloma RPMI8226 cells of NOD/SCID mouse myeloma models, and the change of the volume and speed of oncogenicity in myeloma mouse models were evaluated after Notch1 gene silencing, and ELISA was used to detect the serum expression level of IL-6 and VEGF in the tumor-bearing mice.
RESULTSAfter Notch1 gene was silenced by Notch1-shRNA, the speed of tumor formation was significantly inhibited and the tumor volume was reduced in the tumor-bearing mice, as compared with the control group, and the difference was statistically significant (P<0.05). The serum level of IL-6 and VEGF in the tumor-bearing mice significantly decreased in comparison with the control group (P<0.05 ).
CONCLUSIONThe oncogenicity of myeloma cells in the models NOD/SCID mouse myeloma is significantly inhibited by Notch1 gene-silencing, and its mechanism may relate with the decreased secretory level of IL-6 and VEGF after Notch1 gene silencing. Notch1 gene silencing can be used as a new strategy to treat multiple myeloma.